Search research articles
Contact Us
Filters
Showing results (111-120 of 122) with videos related to
Page
of 13
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
HSR25-146: How Mental Health and Substance Use Drive Cancer Disparities in Urban Communities
Eunhee Choi, Rama Nada, Abdullah Salahie, et al.
Investigative Ophthalmology & Visual Science
|
July 30, 2025
RHO-Associated Retinitis Pigmentosa: Genetics, Phenotype, Natural History, Functional Assays, and Animal Model - In Preparation for Clinical Trials
Malena Daich Varela, Juan Carlos Romo-Aguas, Rosellina Guarascio, et al.
Elife
|
April 9, 2025
High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery
Conor J Howard, Nathan S Abell, Beatriz A Osuna, et al.
Internal Medicine Journal
|
October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Katherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Nature Communications
|
January 21, 2022
Accurate determination of solvation free energies of neutral organic compounds from first principles
Leonid Pereyaslavets, Ganesh Kamath, Oleg Butin, et al.
Cancers
|
March 13, 2024
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191
Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.
Journal of Medicinal Chemistry
|
December 12, 2024
Correction to "Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005"
Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat, Alessandra Tedeschi, Kim Linton, et al.
The Lancet. Oncology
|
July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Journal of Medicinal Chemistry
|
August 6, 2021
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005
Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 122) with videos related to
Sort By:
Page
of 13
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
HSR25-146: How Mental Health and Substance Use Drive Cancer Disparities in Urban Communities
Eunhee Choi, Rama Nada, Abdullah Salahie, et al.
Investigative Ophthalmology & Visual Science
|
July 30, 2025
RHO-Associated Retinitis Pigmentosa: Genetics, Phenotype, Natural History, Functional Assays, and Animal Model - In Preparation for Clinical Trials
Malena Daich Varela, Juan Carlos Romo-Aguas, Rosellina Guarascio, et al.
Elife
|
April 9, 2025
High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery
Conor J Howard, Nathan S Abell, Beatriz A Osuna, et al.
Internal Medicine Journal
|
October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Katherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Nature Communications
|
January 21, 2022
Accurate determination of solvation free energies of neutral organic compounds from first principles
Leonid Pereyaslavets, Ganesh Kamath, Oleg Butin, et al.
Cancers
|
March 13, 2024
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191
Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.
Journal of Medicinal Chemistry
|
December 12, 2024
Correction to "Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005"
Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat, Alessandra Tedeschi, Kim Linton, et al.
The Lancet. Oncology
|
July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Journal of Medicinal Chemistry
|
August 6, 2021
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005
Patrick Papa, Brandon Whitefield, Deborah S Mortensen, et al.
Page
of 13